MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-14-2024
T2 Biosystems Operating Income 2011-2026 | TTOO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.7 M | -55.2 M | -43 M | -41.4 M | -52.1 M | -45.1 M | -53.9 M | -50.9 M | -43.4 M | -30.7 M | -19.7 M | -14.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.7 M | -55.2 M | -41.6 M |
Quarterly Operating Income T2 Biosystems
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.2 M | -9.58 M | -12.6 M | - | -13.6 M | -13.1 M | -13.7 M | - | -15.8 M | -15 M | -14.9 M | - | -12.2 M | -10.8 M | -9.7 M | - | -10.6 M | -8.84 M | -13.6 M | -12.4 M | -12.3 M | -13.8 M | -13.6 M | -13.6 M | -9.17 M | -10.9 M | -11.4 M | -14.4 M | -12.4 M | -13.9 M | -13.1 M | -12.9 M | -11.9 M | -13.3 M | -12.7 M | -11.5 M | -11.2 M | -10.5 M | -10.1 M | -8.84 M | -7.79 M | -7.15 M | -6.91 M | -5.64 M | -4.54 M | -4.91 M | -4.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.54 M | -15.8 M | -11.2 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.1 | -0.62 % | $ 173 M |  China |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 115.14 | -0.29 % | $ 35 B |  USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 18.04 | -1.47 % | $ 961 M | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 167.07 | -3.92 % | $ 8.28 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.22 | 1.51 % | $ 701 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 192.03 | 0.48 % | $ 137 B | USA |
 |
DexCom
DXCM
|
912 M | $ 62.94 | 1.16 % | $ 24.6 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.53 | -1.72 % | $ 500 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 90.55 | -3.5 % | $ 11.4 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 110.43 | -3.29 % | $ 9.11 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.92 | -1.92 % | $ 8.49 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 126.99 | -0.31 % | $ 20.2 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 169.79 | -2.0 % | $ 29.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 274.64 | 0.34 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 76.45 | 0.46 % | $ 5.16 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 496.04 | -0.46 % | $ 14.3 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.78 | 0.53 % | $ 443 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 4.56 | -2.72 % | $ 3.59 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.98 | -0.31 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.44 | 0.32 % | $ 2.05 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 15.9 | 5.48 % | $ 2.06 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.56 | 2.33 % | $ 393 M | USA |
 |
Natera
NTRA
|
-541 M | $ 204.71 | -1.57 % | $ 20.1 B | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.41 | 4.85 % | $ 423 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.12 | 0.04 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
-1.2 M | $ 26.16 | 2.99 % | $ 42 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 6.58 | - | $ 390 M | USA |
 |
RadNet
RDNT
|
62 M | $ 54.92 | 0.23 % | $ 4.13 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.88 | -0.29 % | $ 287 M | USA |
 |
Sotera Health Company
SHC
|
248 M | $ 14.89 | -0.47 % | $ 4.23 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.28 | 32.38 % | $ 2.66 B | USA |